Published in Circulation on August 09, 2010
Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev (2014) 1.51
Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3β and mitochondrial function. BMC Med (2012) 1.11
ALDH2 in alcoholic heart diseases: molecular mechanism and clinical implications. Pharmacol Ther (2011) 1.09
Aldehyde dehydrogenase-2 regulates nociception in rodent models of acute inflammatory pain. Sci Transl Med (2014) 1.06
mTOR-STAT3-notch signalling contributes to ALDH2-induced protection against cardiac contractile dysfunction and autophagy under alcoholism. J Cell Mol Med (2012) 1.02
Mitochondria as a source and target of lipid peroxidation products in healthy and diseased heart. Clin Exp Pharmacol Physiol (2012) 0.94
AMP-dependent kinase and autophagic flux are involved in aldehyde dehydrogenase-2-induced protection against cardiac toxicity of ethanol. Free Radic Biol Med (2011) 0.93
Interaction between sensory C-fibers and cardiac mast cells in ischemia/reperfusion: activation of a local renin-angiotensin system culminating in severe arrhythmic dysfunction. J Pharmacol Exp Ther (2010) 0.93
Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system. Curr Pharm Des (2011) 0.89
Mast Cell: A Multi-Functional Master Cell. Front Immunol (2016) 0.88
Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function. Free Radic Biol Med (2014) 0.86
Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress. Antioxid Redox Signal (2015) 0.86
A non-cardiomyocyte autonomous mechanism of cardioprotection involving the SLO1 BK channel. PeerJ (2013) 0.86
E-NTPDase1/CD39 modulates renin release from heart mast cells during ischemia/reperfusion: a novel cardioprotective role. FASEB J (2014) 0.83
Sex differences in inflammation during atherosclerosis. Clin Med Insights Cardiol (2015) 0.80
Mast Cell Proteases and Inflammation. Drug Discov Today Dis Models (2011) 0.80
Telmisartan protects against microvascular dysfunction during myocardial ischemia/reperfusion injury by activation of peroxisome proliferator-activated receptor γ. BMC Cardiovasc Disord (2013) 0.80
Aldehyde dehydrogenase type 2 activation by adenosine and histamine inhibits ischemic norepinephrine release in cardiac sympathetic neurons: mediation by protein kinase Cε. J Pharmacol Exp Ther (2012) 0.79
IgE receptor-mediated mast-cell renin release. Am J Pathol (2013) 0.79
Histamine H4-receptors inhibit mast cell renin release in ischemia/reperfusion via protein kinase C ε-dependent aldehyde dehydrogenase type-2 activation. J Pharmacol Exp Ther (2014) 0.78
Histamine 3 receptor activation reduces the expression of neuronal angiotensin II type 1 receptors in the heart. J Pharmacol Exp Ther (2011) 0.78
ALDH2 attenuates Dox-induced cardiotoxicity by inhibiting cardiac apoptosis and oxidative stress. Int J Clin Exp Med (2015) 0.78
ALDH2, a novel protector against stroke? Cell Res (2013) 0.77
A master of versatility to the heart's rescue: mast cells and ischemic preconditioning. Circulation (2010) 0.75
Aldehyde dehydrogenase 2 in aplastic anemia, Fanconi anemia and hematopoietic stem cells. Mol Genet Metab (2016) 0.75
Increased expression of microRNA-378a-5p in acute ethanol exposure of rat cardiomyocytes. Cell Stress Chaperones (2017) 0.75
Mitochondrial aldehyde dehydrogenase-2 deficiency compromises therapeutic effect of ALDH bright cell on peripheral ischemia. Redox Biol (2017) 0.75
Inhibition of ALDH2 expression aggravates renal injury in a rat sepsis syndrome model. Exp Ther Med (2017) 0.75
S1P1-mediated anti-RAS cardioprotection: pivotal role of mast cell ALDH2. J Pharmacol Exp Ther (2017) 0.75
Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation (1986) 19.82
Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med (1991) 16.01
Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev (2008) 5.52
Nomenclature and classification of purinoceptors. Pharmacol Rev (1994) 5.32
Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science (2008) 4.32
The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem (1993) 2.66
Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc Natl Acad Sci U S A (1999) 2.44
Adenosine A2B receptors. Pharmacol Rev (1997) 2.38
Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res (1992) 2.31
Signaling pathways in ischemic preconditioning. Heart Fail Rev (2007) 2.26
Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest (2006) 2.25
A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J Biol Chem (1996) 2.16
ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology. J Mol Cell Cardiol (2000) 2.14
Mitochondrial PKC epsilon and mitochondrial ATP-sensitive K+ channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ Res (2006) 2.11
Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends Pharmacol Sci (1994) 1.87
The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res (1999) 1.79
Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A2B and A3 adenosine receptors. Circ Res (2003) 1.71
Retracted Redox regulation of angiotensin II preconditioning of the myocardium requires MAP kinase signaling. J Mol Cell Cardiol (2006) 1.70
Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am J Physiol (1999) 1.61
Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation (2003) 1.60
Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide. Circulation (2004) 1.60
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem (2000) 1.44
Time-dependent and ethanol-induced cardiac protection from ischemia mediated by mitochondrial translocation of varepsilonPKC and activation of aldehyde dehydrogenase 2. J Mol Cell Cardiol (2008) 1.44
Acetylcholine, bradykinin, opioids, and phenylephrine, but not adenosine, trigger preconditioning by generating free radicals and opening mitochondrial K(ATP) channels. Circ Res (2001) 1.43
Why do we still not have cardioprotective drugs? Circ J (2009) 1.40
Effect of A2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J Pharmacol Exp Ther (2007) 1.40
Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol (2007) 1.38
Mast cells: a unique source of renin. Proc Natl Acad Sci U S A (2004) 1.38
Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target? Trends Cardiovasc Med (2009) 1.38
Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther (2007) 1.37
Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. J Mol Cell Cardiol (1999) 1.33
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem (1998) 1.32
Renin: at the heart of the mast cell. Immunol Rev (2007) 1.26
Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J Exp Med (2007) 1.26
Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res (2001) 1.19
Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol (1995) 1.18
Different isozymes of protein kinase C mediate feedback inhibition of phospholipase C and stimulatory signals for exocytosis in rat RBL-2H3 cells. J Biol Chem (1993) 1.12
Critical review of prorenin and (pro)renin receptor research. Hypertension (2008) 1.01
Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. J Cardiovasc Pharmacol (2003) 1.00
Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am J Physiol (1999) 0.97
Ischemic preconditioning: bioenergetic and metabolic changes and the role of endogenous adenosine. J Mol Cell Cardiol (1996) 0.95
Selective blockade of AT1 angiotensin II receptors abolishes ischemic preconditioning in isolated rabbit hearts. J Mol Cell Cardiol (1997) 0.91
In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. J Pharmacol Exp Ther (1992) 0.91
Getting to the heart of proteomics. N Engl J Med (2009) 0.88
Acetaldehyde induces histamine release from human airway mast cells to cause bronchoconstriction. Int Arch Allergy Immunol (2004) 0.88
Functional characterization of an endogenous Xenopus oocyte adenosine receptor. Br J Pharmacol (2002) 0.87
Recent improvements in the development of A(2B) adenosine receptor agonists. Purinergic Signal (2008) 0.86
Estimation of the extent of lipid peroxidation in the ischemic and reperfused heart by monitoring lipid metabolic products with the aid of high-performance liquid chromatography. J Chromatogr (1993) 0.86
Ischemic preconditioning prevents the impairment of hypoxic coronary vasodilatation caused by ischemia/reperfusion: role of adenosine A1/A3 and bradykinin B2 receptor activation. Circ Res (1997) 0.85
5-Hydroxydecanoate and coenzyme A are inhibitors of native sarcolemmal KATP channels in inside-out patches. Biochim Biophys Acta (2009) 0.84
The myocardial no-reflow phenomenon: role of deltaPKC. Cardiovasc Res (2007) 0.79
Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science (2008) 4.32
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation (2008) 2.59
Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest (2006) 2.25
Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J Clin Invest (2013) 1.83
Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation (2003) 1.80
Pharmacological inhibition of epsilon PKC suppresses chronic inflammation in murine cardiac transplantation model. J Mol Cell Cardiol (2007) 1.78
Protein kinase C delta mediates cerebral reperfusion injury in vivo. J Neurosci (2004) 1.71
Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. Cardiovasc Res (2006) 1.70
Preservation of base-line hemodynamic function and loss of inducible cardioprotection in adult mice lacking protein kinase C epsilon. J Biol Chem (2003) 1.63
Protein kinase Cdelta activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. J Biol Chem (2004) 1.62
Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation (2003) 1.60
Cardioprotection by epsilon-protein kinase C activation from ischemia: continuous delivery and antiarrhythmic effect of an epsilon-protein kinase C-activating peptide. Circulation (2004) 1.60
Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant. Nat Struct Mol Biol (2010) 1.57
PKC isozymes in chronic cardiac disease: possible therapeutic targets? Annu Rev Pharmacol Toxicol (2008) 1.51
Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev (2014) 1.51
Epsilon PKC is required for the induction of tolerance by ischemic and NMDA-mediated preconditioning in the organotypic hippocampal slice. J Neurosci (2003) 1.50
Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res (2009) 1.50
Aberrant mitochondrial fission in neurons induced by protein kinase C{delta} under oxidative stress conditions in vivo. Mol Biol Cell (2010) 1.49
Cardioprotection mediated by sphingosine-1-phosphate and ganglioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol (2002) 1.45
Dopamine-induced exocytosis of Na,K-ATPase is dependent on activation of protein kinase C-epsilon and -delta. Mol Biol Cell (2002) 1.45
Time-dependent and ethanol-induced cardiac protection from ischemia mediated by mitochondrial translocation of varepsilonPKC and activation of aldehyde dehydrogenase 2. J Mol Cell Cardiol (2008) 1.44
The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke (2005) 1.44
A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci (2012) 1.42
Cardioprotective mechanisms of PKC isozyme-selective activators and inhibitors in the treatment of ischemia-reperfusion injury. Pharmacol Res (2007) 1.41
Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc Res (2010) 1.39
Mast cells in the periprosthetic breast capsule. Aesthetic Plast Surg (2014) 1.39
Mast cells: a unique source of renin. Proc Natl Acad Sci U S A (2004) 1.38
Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target? Trends Cardiovasc Med (2009) 1.38
Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch Biochem Biophys (2003) 1.37
Epsilon protein kinase C as a potential therapeutic target for the ischemic heart. Cardiovasc Res (2006) 1.35
Reperfusion-induced translocation of deltaPKC to cardiac mitochondria prevents pyruvate dehydrogenase reactivation. Circ Res (2005) 1.34
Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost (2005) 1.32
Mitochondrial import of PKCepsilon is mediated by HSP90: a role in cardioprotection from ischaemia and reperfusion injury. Cardiovasc Res (2010) 1.30
Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases. J Pharmacol Exp Ther (2003) 1.29
Acute inhibition of excessive mitochondrial fission after myocardial infarction prevents long-term cardiac dysfunction. J Am Heart Assoc (2013) 1.28
Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKCvarepsilon) knockout mice. J Mol Cell Cardiol (2009) 1.27
The PKCdelta -Abl complex communicates ER stress to the mitochondria - an essential step in subsequent apoptosis. J Cell Sci (2008) 1.26
Intracellular transport mechanisms of signal transducers. Annu Rev Physiol (2002) 1.26
Renin: at the heart of the mast cell. Immunol Rev (2007) 1.26
The betagamma subunit of heterotrimeric G proteins interacts with RACK1 and two other WD repeat proteins. J Biol Chem (2002) 1.24
Biodistribution of intracellularly acting peptides conjugated reversibly to Tat. Biochem Biophys Res Commun (2004) 1.22
Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta. J Mol Cell Cardiol (2002) 1.20
IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J Immunol (2009) 1.19
Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion. Cardiovasc Res (2009) 1.18
Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. Am J Physiol Renal Physiol (2011) 1.18
Rationally designed peptide regulators of protein kinase C. Trends Endocrinol Metab (2008) 1.17
Suppression of deltaPKC activation after focal cerebral ischemia contributes to the protective effect of hypothermia. J Cereb Blood Flow Metab (2007) 1.17
Sustained pharmacological inhibition of deltaPKC protects against hypertensive encephalopathy through prevention of blood-brain barrier breakdown in rats. J Clin Invest (2008) 1.17
Peptides derived from the C2 domain of protein kinase C epsilon (epsilon PKC) modulate epsilon PKC activity and identify potential protein-protein interaction surfaces. J Biol Chem (2006) 1.16
Impaired sphingolipid synthesis in the respiratory tract induces airway hyperreactivity. Sci Transl Med (2013) 1.16
c-Kit-positive cardiac stem cells nested in hypoxic niches are activated by stem cell factor reversing the aging myopathy. Circ Res (2013) 1.15
Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced cell migration. Cancer Cell (2013) 1.14
Sequential activation of individual PKC isozymes in integrin-mediated muscle cell spreading: a role for MARCKS in an integrin signaling pathway. J Cell Sci (2002) 1.14
Epsilon protein kinase C mediated ischemic tolerance requires activation of the extracellular regulated kinase pathway in the organotypic hippocampal slice. J Cereb Blood Flow Metab (2004) 1.14
deltaPKC participates in the endoplasmic reticulum stress-induced response in cultured cardiac myocytes and ischemic heart. J Mol Cell Cardiol (2007) 1.11
Role of mast cells in renal fibrosis. Kidney Int (2013) 1.11
DeltaPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo. Brain Res (2007) 1.11
Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J Med Chem (2007) 1.11
Insight into intra- and inter-molecular interactions of PKC: design of specific modulators of kinase function. Pharmacol Res (2007) 1.10
Exercise training restores cardiac protein quality control in heart failure. PLoS One (2012) 1.06
A critical intramolecular interaction for protein kinase Cepsilon translocation. J Biol Chem (2004) 1.06
Protein kinase C delta (deltaPKC)-annexin V interaction: a required step in deltaPKC translocation and function. J Biol Chem (2006) 1.06
Protein quality control disruption by PKCβII in heart failure; rescue by the selective PKCβII inhibitor, βIIV5-3. PLoS One (2012) 1.05
Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts. Circulation (2004) 1.04
Dopamine and ethanol cause translocation of epsilonPKC associated with epsilonRACK: cross-talk between cAMP-dependent protein kinase A and protein kinase C signaling pathways. Mol Pharmacol (2008) 1.04
epsilonPKC confers acute tolerance to cerebral ischemic reperfusion injury. Neurosci Lett (2008) 1.04
Protein kinase C delta cleavage initiates an aberrant signal transduction pathway after cardiac arrest and oxygen glucose deprivation. J Cereb Blood Flow Metab (2005) 1.03
Molecular basis of branched peptides resistance to enzyme proteolysis. Chem Biol Drug Des (2007) 1.03
Impairment of hyperpolarization-activated, cyclic nucleotide-gated channel function by the intravenous general anesthetic propofol. J Pharmacol Exp Ther (2005) 1.03
ALDH2 activator inhibits increased myocardial infarction injury by nitroglycerin tolerance. Sci Transl Med (2011) 1.02
Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension (2008) 1.02
Dutch and Arctic mutant peptides of beta amyloid(1-40) differentially affect the FGF-2 pathway in brain endothelium. Exp Cell Res (2008) 1.01
Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors. J Mol Cell Cardiol (2003) 1.00
Protein kinase C epsilon and gamma: involvement in formalin-induced nociception in neonatal rats. J Pharmacol Exp Ther (2004) 1.00
Abeta peptides accelerate the senescence of endothelial cells in vitro and in vivo, impairing angiogenesis. FASEB J (2010) 0.99
Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy. J Mol Cell Cardiol (2011) 0.99
RACK1 regulates Src-mediated Sam68 and p190RhoGAP signaling. Oncogene (2004) 0.98
Histamine H3-receptor-induced attenuation of norepinephrine exocytosis: a decreased protein kinase a activity mediates a reduction in intracellular calcium. J Pharmacol Exp Ther (2004) 0.98
Isozyme-specific inhibitors and activators of protein kinase C. Methods Enzymol (2002) 0.98
Myocardial salvage in acute myocardial infarction--challenges in clinical translation. J Mol Cell Cardiol (2011) 0.98
Mast cell renin and a local renin-angiotensin system in the airway: role in bronchoconstriction. Proc Natl Acad Sci U S A (2008) 0.98
Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings. Proc Natl Acad Sci U S A (2001) 0.97
deltaPKC inhibition or varepsilonPKC activation repairs endothelial vascular dysfunction by regulating eNOS post-translational modification. J Mol Cell Cardiol (2009) 0.97
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) phosphorylation by protein kinase Cδ (PKCδ) inhibits mitochondria elimination by lysosomal-like structures following ischemia and reoxygenation-induced injury. J Biol Chem (2013) 0.97
A personalized medicine approach for Asian Americans with the aldehyde dehydrogenase 2*2 variant. Annu Rev Pharmacol Toxicol (2014) 0.97
Centrosomal PKCbetaII and pericentrin are critical for human prostate cancer growth and angiogenesis. Cancer Res (2008) 0.96
A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo. Clin Cancer Res (2011) 0.96
Molecular dynamics characterization of the C2 domain of protein kinase Cbeta. J Biol Chem (2002) 0.96
Discovery of a novel class of covalent inhibitor for aldehyde dehydrogenases. J Biol Chem (2011) 0.95
Norepinephrine release from the ischemic heart is greatly enhanced in mice lacking histamine H3 receptors. Mol Pharmacol (2003) 0.95
Coupling of angiotensin II AT1 receptors to neuronal NHE activity and carrier-mediated norepinephrine release in myocardial ischemia. Am J Physiol Heart Circ Physiol (2003) 0.94
PKCβII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses. J Cell Mol Med (2011) 0.94